ArticleOncoTargets and therapy2014

Brentuximab vedotin for relapsed or refractory CD30+ Hodgkin lymphoma: a multicenter analysis from Asia.

Qing-Ming Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.